Navigating MIBC management: Integrating ctDNA into clinical practice

NateraConnect Single and Combo Orders

A clinical perspective from Dr. Siddharth Sheth

See how Signatera™ MRD testing flagged HNSCC recurrence before CT imaging, providing a lead-time advantage that can inform treatment.

Redefining HNSCC Management with Signatera™ MRD Testing: A Multidisciplinary Perspective

My patient is Signatera-positive. Now What?

MRD Insights for Radiation Oncology in NSCLC

ASBrS 2026: Optimizing Breast Cancer

Leading Breast Surgeons Discuss MRD Testing

Introducing Signatera, a personalized, tumor-informed test

Driving clinical development with real-world molecular intelligence

Signatera Test

Exploring ctDNA-Guided Management in Melanoma

Advancing Testicular Cancer Care with Personalized ctDNA Testing

Providing assurance in lung cancer with Signatera MRD testing

Shelly and her came team use Signatera MRD testing to stay one step ahead of her lung cancer treatment

Dr. Abhinand Peddada - Signatera for HNSCC early intervention

Signatera Genome: Unlocking the next level of ultrasensitive MRD detection with Phased Variant technology

Marci Invasive Lobular Breast Cancer Patient

Signatera Explainer

MODERN Part 3, CIRB

MODERN Part 2, CIRB